Stereotaxis Publishes Positive Results from MAGiC Catheter Study

Stereotaxis, Inc. (NYSE:STXS) is one of the 10 Best Small Cap Robotics Stocks to Buy Now. On July 1, Stereotaxis, Inc. (NYSE:STXS) published initial clinical results from the MAGiC catheter study. The authors of the study have solid experience and expertise, having treated more than 6,500 robotic procedures with older versions of magnetic catheters.

The study used MAGiC to treat patients suffering from arrhythmia in all four chambers of the heart. The study concluded with record safety and efficacy for 67 patients, with acute efficacy recorded at 94%. Currently, patient enrollment is still ongoing with sustained efficacy rates.

“We are delighted to see the strong efficacy and safety profile of MAGiC published in a prestigious journal. This publication supports our ongoing launch of MAGiC across Europe. We appreciate the pioneering electrophysiologists at Copenhagen University Hospital Rigshospitalet and Vilnius University Hospital Santaros Klinikos who made this possible,” said David Fischel, Stereotaxis Chairman and CEO.

Stereotaxis, Inc. (NYSE:STXS) is an innovative surgical robot developer for minimally invasive endovascular intervention. The company provides innovative solutions to physicians used to treat 150,000 patients across the world to date.

While we acknowledge the potential of STXS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.